8-K: Allurion Announces Preliminary Q1 2024 Results: Revenue and Procedural Volume Growth, Cash Burn Reduced

Allurion reported preliminary first quarter 2024 results showing revenue growth, increased procedural volume, and a significant reduction in cash burn.

Summary

• Allurion Technologies has released preliminary, unaudited financial results for the first quarter of 2024.
• Revenue is estimated to be between $9.2 million and $9.3 million, representing a 12-13% increase compared to the fourth quarter of 2023.
• Procedural volume, measured by new app users, grew by approximately 22% compared to the previous quarter.
• The company significantly reduced its cash burn to between $8 million and $9 million, down from $22 million in the fourth quarter of 2023.
• This cash burn is in line with the company's target of approximately $30 million for the full year.
• Full financial results for the first quarter will be released on May 14, 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue and procedural volume growth, coupled with a significant reduction in cash burn. While the results are preliminary, the overall tone is optimistic and suggests the company is on a positive trajectory.

Positives

• The company experienced strong revenue growth of 12-13% compared to the previous quarter.
• Procedural volume increased significantly by 22% quarter-over-quarter.
• Allurion has made substantial progress in reducing its cash burn, down from $22 million to $8-9 million.
• The company's performance is in line with its targeted cash burn for the year.
• The launch of the Allurion Virtual Care Suite in the US and first reimbursed procedures in the UK are expected to be catalysts for future growth.

Negatives

• The reported results are preliminary and unaudited, and actual results may vary.
• The company is still experiencing a cash burn, although it has been significantly reduced.

Risks

• The company's ability to obtain regulatory approval and successfully commercialize the Allurion Program is a risk.
• The timing and results of clinical studies and trials could impact the company's performance.
• The evolution of the markets and the rise of GLP-1 drugs pose a competitive risk.
• The company faces risks related to defending its intellectual property and satisfying regulatory requirements.
• External factors such as the COVID-19 pandemic, the Russia-Ukraine war, and the Israel-Hamas war could impact the business.
• Economic downturns and changes in the regulatory landscape could also pose risks.

Future Outlook

The company expects continued growth in awareness and demand for the Allurion Program, driven by recent catalysts such as the launch of the Virtual Care Suite in the US and reimbursements in the UK. They anticipate the business will continue to improve in subsequent quarters.

Management Comments

• Dr. Shantanu Gaur, Founder and CEO, stated they are encouraged by the growth in revenue and procedural volume while slowing the cash burn rate.
• Management believes awareness and demand for the Allurion Program will continue to grow.

Industry Context

This announcement comes as the weight loss industry is seeing increased interest in both medical devices and pharmaceutical solutions. Allurion's focus on a procedure-less gastric balloon and virtual care suite positions it to compete in this evolving market.

Comparison to Industry Standards

• While specific competitor data is not provided in this document, Allurion's 12-13% quarter-over-quarter revenue growth is a positive sign in the medical device sector, where growth rates can vary significantly depending on the product lifecycle and market adoption.
• The 22% growth in procedural volume suggests strong market interest in their program, which is a key metric for companies in the weight loss space.
• The reduction in cash burn from $22 million to $8-9 million is a significant improvement and indicates progress towards financial sustainability, which is often a concern for growth-stage medical device companies.
• Companies like ResMed (RMD) and Intuitive Surgical (ISRG) are established players in the medical device space, and while they operate in different areas, their financial performance and growth trajectories serve as benchmarks for companies like Allurion.

Stakeholder Impact

• Shareholders will likely view the preliminary results positively due to the revenue growth and reduced cash burn.
• Employees may be encouraged by the company's progress and positive outlook.
• Customers may be attracted to the growing demand for the Allurion Program.
• Suppliers and creditors may see the company as a more stable and reliable partner.

Next Steps

• The company will release full first quarter 2024 financial results on May 14, 2024.
• A conference call will be held on May 14, 2024, to discuss the results and provide a business update.

Key Dates

Keywords

Allurion, weight loss, gastric balloon, obesity, revenue, procedural volume, cash burn, virtual care, medical device, healthcare